– USA, NY – AiTA Bio, a pioneering bio-MEMS company based in New York City revolutionizing the healthcare technology landscape, announced the appointment of Rich Ferrari to its Board of Directors.
About Rich Ferrari
Rich Ferrari, an esteemed medical technology executive and venture capitalist, joins AiTA Bio’s Board of Directors. Rich is a Co-Founder and Managing Director of De Novo Ventures, a $650M venture capital fund focused on medical devices and biotechnology. Most recently, Rich served as Chairman and CEO of PQ Bypass, which was acquired by Endologix for $300M+. Over his 40-year career, Rich has been a serial entrepreneur founding 6 companies (culminating in 2 IPOs and 4 acquisitions) and has helped architect more than $2B in acquisitions. His unparalleled experience in medical device innovation, venture investing, and leading companies through FDA-required clinical trials will be crucial in guiding AiTA Bio through its journey of leveraging semiconductor technology to
About AiTA Bio Inc.
AiTA Bio Inc. is a bio-MEMS technology company focused on developing an intelligent sensing and delivery, next-generation drug delivery platform. The company has leveraged its drug delivery chip technology to develop the first all-in-one insulin pump and continuous glucose monitoring product for the treatment of Type 1 Diabetes Mellitus.
AiTA Bio is Headquartered in New York City
For more information: https://www.aitabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
